is predicted to increase the exposure to imatinib.

Study → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the risk of toxicity when

given with irinotecan. Avoid.oStudy → Also see TABLE 15

p. 1378

▶ Idelalisib is predicted to increase the exposure to ivabradine.

Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to ivacaftor.

Adjust ivacaftor p. 293 or lumacaftor with ivacaftor p. 294 or

tezacaftor with ivacaftor p. 295 dose with potent inhibitors of

CYP3A4.rStudy

▶ Idelalisib is predicted to increase the exposure to lapatinib.

Avoid.oStudy

▶ Idelalisib is predicted to markedly increase the exposure to

lomitapide. Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to lurasidone.

Avoid.rStudy

▶ Idelalisib

o

is predicted to increase the exposure to macitentan.

Study

▶ Idelalisib markedly increases the exposure to maraviroc.

Adjust dose.rTheoretical

▶ Idelalisib is predicted to markedly to very markedly increase

the exposure to midazolam. Avoid or adjust dose.rStudy

▶ Idelalisib is predicted to very markedly increase the exposure

to midostaurin. Avoid or monitor for toxicity.rStudy

▶ Idelalisib is predicted to increase the exposure to mirabegron.

Adjust mirabegron dose in hepatic and renal impairment,

p. 781.oStudy

▶ Idelalisib

o

is predicted to increase the exposure to mirtazapine.

Study

▶ Mitotane is predicted to decrease the exposure to idelalisib.

Avoid.rStudy → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the exposure to modafinil.

nTheoretical

▶ Idelalisib is predicted to increase the exposure to monoclonal

antibodies (trastuzumab emtansine). Avoid.rTheoretical →

Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to markedly increase the exposure to

naloxegol. Avoid.rStudy

▶ Idelalisib

o

is predicted to increase the exposure to netupitant.

Study

▶ Nevirapine is predicted to decrease the exposure to idelalisib.

Avoid.oTheoretical

▶ Idelalisib is predicted to moderately increase the exposure to

nilotinib. Avoid.rStudy → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the exposure to nitisinone.

Adjust dose.oTheoretical

▶ Idelalisib is predicted to increase the exposure to olaparib.

Avoid potent inhibitors of CYP3A4 or adjust olaparib dose,

p. 1005.oStudy → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the exposure to opioids

(alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil).

Monitor and adjust dose.rStudy

▶ Idelalisib is predicted to increase the exposure to opioids

(methadone).rTheoretical

▶ Idelalisib is predicted to increase the exposure to ospemifene.

Avoid in poor CYP2C9 metabolisers.oStudy

▶ Idelalisib is predicted to increase the exposure to oxybutynin.

nStudy

▶ Idelalisib is predicted to increase the exposure to palbociclib.

Avoid or adjust palbociclib dose, p. 992.rStudy

▶ Idelalisib is predicted to increase the exposure to

panobinostat. Adjust panobinostat dose; in hepatic

impairment avoid, p. 936.oStudy → Also see TABLE 15

p. 1378

▶ Paritaprevir is predicted to increase the exposure to idelalisib.

Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to pazopanib.

Avoid or adjust pazopanib dose, p. 993.oStudy → Also see

TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the exposure to

r

phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid.

Study

▶ Idelalisib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (sildenafil). Avoid potent

inhibitors of CYP3A4 or adjust

Study

sildenafil dose, p. 813.r

▶ Idelalisib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (tadalafil). Use with caution

or avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to pimozide.

Avoid.rStudy

1470 Idelalisib — Idelalisib BNF 78

Interactions | Appendix 1

A1

▶ Idelalisib is predicted to slightly increase the exposure to

ponatinib

Study

. Monitor and adjust ponatinib dose, p. 994.o ▶ Idelalisib is predicted to moderately increase the exposure to

praziquantel.nStudy

▶ Idelalisib is predicted to increase the exposure to quetiapine.

Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to ranolazine.

Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to reboxetine.

Avoid.oStudy

▶ Idelalisib is predicted to increase the exposure to regorafenib.

Avoid.oStudy → Also see TABLE 15 p. 1378

▶ Idelalisib

o

is predicted to increase the exposure to repaglinide.

Study

▶ Idelalisib is predicted to increase the exposure to retinoids

(alitretinoin)

Theoretical

. Adjust alitretinoin dose, p. 1262.o ▶ Idelalisib is predicted to increase the exposure to ribociclib.

Avoid or adjust ribociclib dose, p. 997.oStudy

▶ Rifampicin is predicted to decrease the exposure to idelalisib.

Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to risperidone.

Adjust dose.oStudy

▶ Idelalisib is predicted to increase the exposure to ruxolitinib.

Adjust dose and monitor side effects.oStudy → Also see

TABLE 15 p. 1378

▶ Idelalisib

o

is predicted to increase the exposure to saxagliptin.

Study

▶ Idelalisib is predicted to increase the concentration of

sirolimus. Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to solifenacin.

Adjust solifenacin p. 779 or tamsulosin with solifenacin p. 786

dose; avoid in hepatic and renal impairment.rStudy

▶ Idelalisib is predicted to moderately increase the exposure to

SSRIs (dapoxetine). Avoid potent inhibitors of CYP3A4 or

adjust dapoxetine dose, p. 821.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

idelalisib. Avoid.oTheoretical

▶ Idelalisib is predicted to increase the exposure to statins

(atorvastatin). Avoid or adjust dose and monitor

rhabdomyolysis.rStudy

▶ Idelalisib is predicted to increase the exposure to statins

(simvastatin). Avoid.rStudy

▶ Idelalisib is predicted to slightly increase the exposure to

sunitinib

Study → Also see

. Avoid or adjust

TABLE 15 p. 1378

sunitinib dose, p. 999.o ▶ Idelalisib is predicted to increase the concentration of

tacrolimus. Monitor and adjust dose.rStudy

▶ Idelalisib is predicted to increase the exposure to taxanes

(cabazitaxel). Avoid.rStudy → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to moderately increase the exposure to

taxanes (docetaxel). Avoid or adjust dose.rStudy → Also

see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the exposure to taxanes

(paclitaxel).rTheoretical → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the concentration of

temsirolimus. Avoid.rTheoretical → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the exposure to tezacaftor.

Adjust tezacaftor with ivacaftor p. 295 dose with potent

inhibitors of CYP3A4.rStudy

▶ Idelalisib is predicted to markedly increase the exposure to

ticagrelor. Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to tofacitinib.

Adjust tofacitinib dose, p. 1105.oStudy

▶ Idelalisib is predicted to increase the exposure to tolterodine.

Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to tolvaptan.

Manufacturer advises caution or adjust tolvaptan dose with

potent inhibitors of CYP3A4, p. 669.rStudy

▶ Idelalisib

o

is predicted to increase the exposure to toremifene.

Theoretical

▶ Idelalisib is predicted to increase the exposure to trabectedin.

Avoid or adjust dose.rTheoretical → Also see TABLE 15

p. 1378

▶ Idelalisib is predicted to moderately increase the exposure to

trazodone. Avoid or adjust dose.oStudy

▶ Idelalisib is predicted to increase the exposure to ulipristal.

Avoid if used for uterine fibroids.rStudy

▶ Idelalisib

r

is predicted to increase the exposure to vemurafenib.

Theoretical

▶ Idelalisib is predicted to increase the exposure to venetoclax.

Avoid or adjust dose—consult product literature.rStudy

▶ Idelalisib

o

is predicted to increase the exposure to venlafaxine.

Study

▶ Idelalisib is predicted to increase the exposure to vinca

alkaloids.rTheoretical → Also see TABLE 15 p. 1378

▶ Idelalisib is predicted to increase the exposure to vitamin D

substances (paricalcitol).oStudy

▶ Idelalisib is predicted to increase the exposure to zopiclone.

Adjust dose.oTheoretical

Ifosfamide → see alkylating agents

Iloprost → see TABLE 4 p. 1375 (antiplatelet effects)

Imatinib → see TABLE 15 p. 1378 (myelosuppression)

▶ Imatinib

o

is predicted to increase the exposure to abemaciclib.

Study

▶ Imatinib is predicted to increase the exposure to aldosterone

antagonists

Study

(eplerenone). Adjust eplerenone dose, p. 193.r

▶ Imatinib is predicted to increase the exposure to alpha blockers

(tamsulosin).oTheoretical

▶ Imatinib

r

is predicted to increase the exposure to alprazolam.

Study

▶ Imatinib is predicted to increase the exposure to

antiarrhythmics (dronedarone).rTheoretical

▶ Imatinib is predicted to increase the exposure to

antiarrhythmics

o

(propafenone). Monitor and adjust dose.

Study

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to imatinib. Avoid.oStudy

▶ Antiepileptics (oxcarbazepine) decrease the exposure to

imatinib. Avoid.oStudy

▶ Antifungals, azoles (fluconazole, posaconazole) are predicted to

increase the exposure to imatinib.oTheoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to imatinib.oStudy

▶ Imatinib is predicted to decrease the exposure to antifungals,

azoles (isavuconazole).oTheoretical

▶ Imatinib is predicted to increase the exposure to antihistamines,

non-sedating (mizolastine).rTheoretical

▶ Imatinib is predicted to increase the exposure to antihistamines,

non-sedating (rupatadine). Avoid.oStudy

▶ Imatinib is predicted to increase the concentration of

antimalarials (piperaquine).rTheoretical

▶ Aprepitant

o

is predicted to increase the exposure to imatinib.

Theoretical

▶ Asparaginase is predicted to increase the risk of hepatotoxicity

when given with imatinib.rTheoretical → Also see TABLE 15

p. 1378

▶ Imatinib

o

is predicted to increase the exposure to axitinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the exposure to bedaquiline.

Avoid prolonged use.nTheoretical

▶ Bosentan

o

is predicted to decrease the exposure to imatinib.

Study

▶ Imatinib is predicted to increase the exposure to bosutinib.

Avoid or adjust dose.rTheoretical → Also see TABLE 15

p. 1378

▶ Imatinib is predicted to increase the exposure to buspirone.

Use with caution and adjust dose.oStudy

▶ Imatinib

o

is predicted to increase the exposure to cabozantinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to imatinib.oTheoretical

▶ Imatinib is predicted to increase the exposure to calcium

channel blockers (amlodipine, felodipine, lacidipine,

lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and

adjust dose.oStudy

BNF 78 Idelalisib — Imatinib 1471

Interactions | Appendix 1

A1

Imatinib (continued)

▶ Imatinib is predicted to increase the exposure to cariprazine.

Avoid.rStudy

▶ Imatinib

o

is predicted to increase the exposure to ceritinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the concentration of

ciclosporin.rStudy

▶ Cobicistat

o

is predicted to increase the exposure to imatinib.

Study

▶ Imatinib

r

is predicted to increase the exposure to cobimetinib.

Theoretical

▶ Imatinib is predicted to increase the exposure to colchicine.

Adjust colchicine dose with moderate inhibitors of CYP3A4,

p. 1120.rStudy

▶ Imatinib is predicted to increase the exposure to corticosteroids

(methylprednisolone). Monitor and adjust dose.oStudy

▶ Imatinib is predicted to increase the risk of bleeding events

when given with coumarins.rTheoretical

▶ Crisantaspase is predicted to increase the risk of

hepatotoxicity when given with imatinib.rTheoretical →

Also see TABLE 15 p. 1378

▶ Imatinib is predicted to slightly increase the exposure to

darifenacin.oStudy

▶ Imatinib

r

is predicted to increase the exposure to dasatinib.

Study → Also see TABLE 15 p. 1378

▶ Imatinib increases the risk of QT-prolongation when given

with domperidone. Avoid.rStudy

▶ Imatinib is predicted to increase the exposure to dopamine

receptor agonists (bromocriptine).rTheoretical

▶ Imatinib is predicted to increase the concentration of

dopamine receptor agonists (cabergoline).oAnecdotal

▶ Imatinib is predicted to moderately increase the exposure to

dutasteride.nStudy

▶ Efavirenz

o

is predicted to decrease the exposure to imatinib.

Study

▶ Imatinib is predicted to increase the exposure to eliglustat.

Avoid or adjust dose—consult product literature.rStudy

▶ Imatinib is predicted to moderately increase the exposure to

encorafenib.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

imatinib. Avoid.oStudy

▶ Imatinib is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Imatinib is predicted to increase the risk of ergotism when

given with ergotamine.rTheoretical

▶ Imatinib

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Imatinib is predicted to increase the concentration of

everolimus. Avoid or adjust dose.oStudy → Also see

TABLE 15 p. 1378

▶ Imatinib is predicted to increase the exposure to fesoterodine.

Adjust fesoterodine dose with moderate inhibitors of CYP3A4

in hepatic and renal impairment, p. 777.nStudy

▶ Imatinib

o

is predicted to increase the exposure to gefitinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Grapefruit juice is predicted to increase the exposure to

imatinib.oTheoretical

▶ Imatinib is predicted to increase the concentration of

guanfacine. Adjust guanfacine dose, p. 352.oTheoretical

▶ HIV-protease inhibitors are predicted to increase the exposure

to imatinib.oStudy

▶ Imatinib is predicted to increase the exposure to ibrutinib.

Adjust ibrutinib dose with moderate inhibitors of CYP3A4,

p. 983.rStudy → Also see TABLE 15 p. 1378

▶ Idelalisib

o

is predicted to increase the exposure to imatinib.

Study → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the exposure to ivabradine.

Adjust ivabradine dose, p. 211.rTheoretical

▶ Imatinib is predicted to increase the exposure to ivacaftor.

Adjust ivacaftor p. 293 or tezacaftor with ivacaftor p. 295 dose

with moderate inhibitors of CYP3A4.rStudy

▶ Imatinib

o

is predicted to increase the exposure to lapatinib.

Study

▶ Imatinib is predicted to increase the exposure to lomitapide.

Avoid.oTheoretical

▶ Imatinib is predicted to increase the exposure to lurasidone.

Adjust lurasidone dose, p. 398.oStudy

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to imatinib.oStudy

▶ Macrolides (erythromycin) are predicted to increase the

exposure to imatinib.oTheoretical

▶ Imatinib is predicted to increase the exposure to midazolam.

Monitor side effects and adjust dose.rStudy

▶ Imatinib

o

is predicted to increase the exposure to midostaurin.

Theoretical

▶ Mitotane is predicted to decrease the exposure to imatinib.

Avoid.oStudy → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the exposure to naloxegol.

Adjust

Study

naloxegol dose and monitor side effects, p. 65.o ▶ Netupitant

o

is predicted to increase the exposure to imatinib.

Theoretical

▶ Nevirapine

o

is predicted to decrease the exposure to imatinib.

Study

▶ Imatinib is predicted to increase the exposure to olaparib.

Avoid moderate inhibitors of CYP3A4 or adjust olaparib dose,

p. 1005.oTheoretical → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the exposure to opioids

(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and

adjust dose.oStudy

▶ Imatinib is predicted to increase the exposure to opioids

(methadone, sufentanil).oTheoretical

▶ Imatinib is predicted to increase the exposure to oxybutynin.

nTheoretical

▶ Imatinib increases the risk of hepatotoxicity when given with

paracetamol.rAnecdotal

▶ Imatinib

o

is predicted to increase the exposure to pazopanib.

Theoretical → Also see TABLE 15 p. 1378

▶ Pegaspargase is predicted to increase the risk of

hepatotoxicity when given with imatinib.rTheoretical →

Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the risk of bleeding events

when given with phenindione.rTheoretical

▶ Imatinib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil

dose, p. 812.oTheoretical

▶ Imatinib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (sildenafil). Monitor or

adjust sildenafil dose with moderate inhibitors of CYP3A4,

p. 813.oStudy

▶ Imatinib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors (tadalafil).rTheoretical

▶ Imatinib is predicted to increase the exposure to

phosphodiesterase type-5 inhibitors

r

(vardenafil). Adjust dose.

Theoretical

▶ Imatinib is predicted to increase the exposure to pimozide.

Avoid.rTheoretical

▶ Imatinib is predicted to increase the exposure to quetiapine.

Avoid.oStudy

▶ Imatinib

r

is predicted to increase the exposure to ranolazine.

Study

▶ Imatinib

o

is predicted to increase the exposure to ribociclib.

Study

▶ Rifampicin is predicted to decrease the exposure to imatinib.

Avoid.oStudy

▶ Imatinib

o

is predicted to increase the exposure to ruxolitinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the exposure to saxagliptin.

nStudy

▶ Imatinib increases the concentration of sirolimus. Monitor and

adjust dose.oStudy

▶ Imatinib is predicted to increase the exposure to SSRIs

(dapoxetine). Adjust dapoxetine dose with moderate inhibitors

of CYP3A4, p. 821.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

imatinib.oStudy

▶ Imatinib is predicted to increase the exposure to statins

(atorvastatin). Monitor and adjust dose.rStudy

1472 Imatinib — Imatinib BNF 78

Interactions | Appendix 1

A1

▶ Imatinib is predicted to increase the exposure to statins

(simvastatin). Use with caution and adjust simvastatin dose,

p. 205.rStudy

▶ Imatinib

o

is predicted to increase the exposure to sunitinib.

Theoretical → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the concentration of

tacrolimus.rStudy

▶ Imatinib is predicted to increase the exposure to taxanes

(cabazitaxel).oTheoretical → Also see TABLE 15 p. 1378

▶ Tedizolid is predicted to increase the exposure to imatinib.

Avoid.oTheoretical

▶ Imatinib is predicted to increase the concentration of

temsirolimus.oTheoretical → Also see TABLE 15 p. 1378

▶ Imatinib is predicted to increase the exposure to tezacaftor.

Adjust tezacaftor with ivacaftor p. 295 dose with moderate

inhibitors of CYP3A4.rStudy

▶ Imatinib given with a potent CYP2C19 inhibitor is predicted to

increase the exposure to tofacitinib. Adjust tofacitinib dose,

p. 1105.oStudy

▶ Imatinib is predicted to increase the exposure to tolterodine.

nTheoretical

▶ Imatinib is predicted to increase the exposure to tolvaptan.

Manufacturer advises caution or adjust tolvaptan dose with

moderate inhibitors of CYP3A4, p. 669.oStudy

▶ Imatinib

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more